CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.59 USD
-0.01 (-0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Brokerage Reports
0 items in cart
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 101 - 120 ( 149 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional CX-2009 Data Presented at AACR Reaffirms Our Optimism; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Chief Financial Officer Stepping Down; Replacement Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Focus Ahead on Clinical Execution
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
R-D Day: Encouraging First Look at CX-2009 Clinical Data
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Weakness Creates Buying Opportunity as R-D Day Validates Probody Platform; Reiterate Buy; Raising Target to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; CX-2009 Update and CX-072 SITC Data Encouraging; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; CX-2009 Passes through Dose-Escalation; SITC Event Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2018 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our CX-072 Assessment Remains Unchanged Post-ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-072 Update Continues to Support Differentiated Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R